Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by StockNews com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright restated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $48.00 price objective on the biotechnology company’s stock. ENTA has been the subject of a number of other reports. Oppenheimer reduced their price target on shares […]
WATERTOWN, Mass. (BUSINESS WIRE) Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respirator.
Enanta Pharmaceuticals, Inc. , a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral,.